Nebraska Medicine, a $2.5bn academic health system based in Omaha, has partnered with Mevion Medical Systems to provide advanced cancer care options for its patients.
Under the partnership, Nebraska Medicine will integrate Mevion Medical Systems’ proton therapy into the Fred & Pamela Buffett Cancer Center in the US.
Nebraska Medicine is the academic partner of the University of Nebraska Medical Center (UNMC). Fred & Pamela Buffett Cancer Center is UNMC’s cancer centre project in midtown Omaha, Nebraska.
The adoption of the MEVION S250-FIT proton therapy system marks the second National Cancer Institute (NCI)-designated cancer centre to use the solution.
According to Mevion Medical Systems, the proton therapy system could also be one of the first S250-FIT installations, joining Stanford Health Care, BayCare, and Atlantic Health.
The MEVION S250-FIT system will be integrated into an unfinished treatment room at the radiation oncology department of the Fred & Pamela Buffett Cancer Center.
The partnership is part of Nebraska Medicine’s commitment to offer advanced cancer care options in one convenient location.
Mevion Medical Systems CEO and president Tina Yu said: “The MEVION S250-FIT represents a major advancement in proton therapy accessibility and affordability, and we are proud to collaborate with Nebraska Medicine in their mission to provide world-class treatment options.”
The MEVION S250-FIT system features a compact design, upright patient positioning, and HYPERSCAN pencil beam scanning technology.
It also has FLASH research capabilities and dual-energy large bore diagnostic CT for image-guided radiation therapy.
Mevion Medical said the system’s precision minimises damage to surrounding healthy tissue, playing a key role in paediatric patients and tumours in sensitive areas like the head, neck, breast, lung, abdomen, and pelvis.
UNMC’s academic partner has also collaborated with H&H Design-Build and Kiewit in exploring the integration of this proton therapy system into its cancer centre.
Nebraska Medicine CEO and board chair James Linder said: “Nebraska Medicine is committed to providing our patients with the most advanced cancer care available.
“The support of the donor community has enabled the addition of proton therapy to the Fred & Pamela Buffett Cancer Center and marks another important step in fulfilling that commitment.”
Earlier this month, Nebraska Medicine, has signed a contract to use Palantir Technologies’ Artificial Intelligence Platform (AIP) to help improve healthcare through transformational technologies.
